Canaccord analyst Whitney Ijem lowered the firm’s price target on Intellia Therapeutics to $65 from $66 and keeps a Buy rating on the shares. The firm said the company’s 2Q23 earnings were incremental, relative to Q1, with key clinical programs on track for the second half of the year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- 3 Best Stocks to Buy Now, 8/7/2023, According to Top Analysts
- Intellia Therapeutics price target lowered to $40 from $44 at Citi
- Cathie Wood’s ARK Investment bought 95.2K shares of Intellia Therapeutics today
- Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q2 EPS ($1.40), consensus ($1.32)